Mortality, sepsis, and organ failure in hospitalized patients with cirrhosis vary by type of infection.
Nationwide Readmissions Database
acute-on-chronic liver failure
decompensated cirrhosis
pneumonia
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
11
07
2021
received:
26
02
2021
accepted:
16
07
2021
pubmed:
23
7
2021
medline:
17
3
2022
entrez:
22
7
2021
Statut:
ppublish
Résumé
Infection is associated with substantial morbidity and mortality in cirrhosis, but presumably, not all infections carry the same risk of mortality. We compared outcomes of different sites of infection in a nationally representative sample of inpatients with cirrhosis. We queried the Nationwide Readmissions Database for patients with cirrhosis from 2011 to 2014. Cirrhosis and infection diagnoses were identified by previously used algorithms of ICD-9 codes. The following infections were compared: urinary tract infection (UTI), pneumonia, cellulitis, spontaneous bacterial peritonitis (SBP), and Clostridium difficile infection (CDI). The primary outcome was inpatient mortality. Secondary outcomes included sepsis, any organ failure, multiple organ failures, and 30-day readmission. Outcomes were analyzed using logistic regression and included a priori covariates. A total of 1 798 830 weighted index admissions were identified. Infection was present in 29.2% overall-including UTI (13.7%), pneumonia (8.9%), cellulitis (5.2%), CDI (2.8%), and SBP (2.0%). Mortality was significantly higher in pneumonia (19.6%), SBP (18.6%), and CDI (17.4%) compared with cellulitis (7.6%) and UTI (11.8%). Sepsis, any, and multiple organ failures were most commonly seen in pneumonia, SBP, and CDI. Multivariable analysis demonstrated that pneumonia had the highest associated mortality (odds ratio [OR] 2.73, confidence interval [CI] 2.68-2.80) and multiple organ failures (OR 3.59, CI 3.50-3.68). Significantly increased 30-day readmission was seen only with SBP (24.9%). Outcomes of inpatients with cirrhosis vary significantly depending on the type of infection. The severity and epidemiology of infection in cirrhosis appears to be shifting with pneumonia, not SBP, having the highest prevalence of multiple organ failures and inpatient mortality.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Infection is associated with substantial morbidity and mortality in cirrhosis, but presumably, not all infections carry the same risk of mortality. We compared outcomes of different sites of infection in a nationally representative sample of inpatients with cirrhosis.
METHODS
METHODS
We queried the Nationwide Readmissions Database for patients with cirrhosis from 2011 to 2014. Cirrhosis and infection diagnoses were identified by previously used algorithms of ICD-9 codes. The following infections were compared: urinary tract infection (UTI), pneumonia, cellulitis, spontaneous bacterial peritonitis (SBP), and Clostridium difficile infection (CDI). The primary outcome was inpatient mortality. Secondary outcomes included sepsis, any organ failure, multiple organ failures, and 30-day readmission. Outcomes were analyzed using logistic regression and included a priori covariates.
RESULTS
RESULTS
A total of 1 798 830 weighted index admissions were identified. Infection was present in 29.2% overall-including UTI (13.7%), pneumonia (8.9%), cellulitis (5.2%), CDI (2.8%), and SBP (2.0%). Mortality was significantly higher in pneumonia (19.6%), SBP (18.6%), and CDI (17.4%) compared with cellulitis (7.6%) and UTI (11.8%). Sepsis, any, and multiple organ failures were most commonly seen in pneumonia, SBP, and CDI. Multivariable analysis demonstrated that pneumonia had the highest associated mortality (odds ratio [OR] 2.73, confidence interval [CI] 2.68-2.80) and multiple organ failures (OR 3.59, CI 3.50-3.68). Significantly increased 30-day readmission was seen only with SBP (24.9%).
CONCLUSIONS
CONCLUSIONS
Outcomes of inpatients with cirrhosis vary significantly depending on the type of infection. The severity and epidemiology of infection in cirrhosis appears to be shifting with pneumonia, not SBP, having the highest prevalence of multiple organ failures and inpatient mortality.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3363-3370Informations de copyright
© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J. Hepatol. 2016; 8: 307.
Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 2011; 9: 727-738.
Fernandez J, Arroyo V. Bacterial infections in cirrhosis: a growing problem with significant implications. Clin. Liver Dis. 2013; 2: 102-105.
Bajaj JS. Altered Microbiota in Cirrhosis and Its Relationship to the Development of Infection. Clin. Liver Dis. 2019; 14: 107.
Martin Mateos R, Albillos A. Sepsis in patients with cirrhosis awaiting liver transplantation: new trends and management. Liver Transpl. 2019; 25: 1700-1709.
Bajaj JS, O'Leary JG, Reddy KR et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014; 60: 250-256.
Cullaro G, Sharma R, Trebicka J, Cárdenas A, Verna EC. Precipitants of acute-on-chronic liver failure: an opportunity for preventative measures to improve outcomes. Liver Transpl. 2020; 26: 283-293.
O'Leary JG, Reddy KR, Garcia-Tsao G et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology 2018; 67: 2367-2374.
Moreau R, Jalan R, Gines P et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144.
Arvaniti V, D'Amico G, Fede G et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-1256.
Rosenblatt RE, Shen N, Tafesh ZH et al. The NACSELD-ACLF score accurately predicts survival: an external validation using a national cohort. Liver Transpl. 2019; 144: 1426-1437.
Kanwal F, Tansel A, Kramer J, Feng H, Asch S, El-Serag HB. Trends in 30-day and 1-year mortality among patients hospitalized with cirrhosis from 2004 to 2013. Am J Gastroenterolerican J. Gastroenterol. 2017; 112: 1287-1297.
Fernández J, Acevedo J, Castro M et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-1561.
Runyon BA. AASLD PRACTICE GUIDELINE management of adult patients with ascites due to cirrhosis: update 2012. Hepatology 2013; 57: 1651-1653. Available from. https://doi.org/10.1002/hep.26359.
Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 1999; 341: 403-409.
Rosenblatt R, Shen N, Mehta A et al. Clostridium difficile infections in hospitalized advanced cirrhotics: increasingly prevalent but less fatal. Liver Int. 2019; 39: 1263-1270.
Bajaj JS, O'Leary JG, Reddy KR et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the north American Consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012; 56: 2328-2335.
Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin. Gastroenterol. Hepatol. 2016; 14: 1181-1188.e2.
Mellinger JL, Richardson CR, Mathur AK, Volk ML. Variation among United States hospitals in inpatient mortality for cirrhosis. Clin. Gastroenterol. Hepatol. 2015; 13: 577-584.
Rosenblatt R, Cohen-Mekelburg S, Shen N et al. Cirrhosis as a comorbidity in conditions subject to the hospital readmissions reduction program. Am. J. Gastroenterol. 2019; 114: 1488-1495.
Rosenblatt R, Tafesh Z, Shen N et al. Early paracentesis in high-risk hospitalized patients. Am. J. Gastroenterol. 2019; 114: 1863-1869.
Mumtaz K, Issak A, Porter K et al. Validation of risk score in predicting early readmissions in decompensated cirrhotic patients: a model based on the administrative database. Hepatology 2019.
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med. Care 1998; 36: 8-27.
Hung TH, Tseng CW, Hsieh YH, Tseng KC, Tsai CC, Tsai CC. High mortality of pneumonia in cirrhotic patients with ascites. BMC Gastroenterol. 2013; 13: 1-6.
Sundaram V, May FP, Manne V, Saab S. Effects of clostridium difficile infection in patients with alcoholic hepatitis. Clin. Gastroenterol. Hepatol. 2014; 12: 1745-1752.
McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 2018; 66: e1-e48.
Kruger AJ, Aberra F, Black SM et al. A validated risk model for prediction of early readmission in patients with hepatic encephalopathy. Ann. Hepatol. 2019; 18: 310-317.
Singal A, Salameh H, Kamath PS. Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States. Aliment. Pharmacol. Ther. 2014; 40: 105-112. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/24832591.
Fernández J, Acevedo J, Prado V et al. Clinical course and short-term mortality of cirrhotic patients with infections other than spontaneous bacterial peritonitis. Liver Int. 2017; 37: 385-395.
Rubin J, Sundaram V, Lai JC. Gender differences among patients hospitalized with cirrhosis in the United States. J. Clin. Gastroenterol. 2020; 54: 83-89.
Fernández J, Prado V, Trebicka J et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J. Hepatol. 2019; 70: 398-411.
Reuken PA, Stallmach A, Bruns T. Mortality after urinary tract infections in patients with advanced cirrhosis-relevance of acute kidney injury and comorbidities. Liver Int. 2013; 33: 220-230.
Sood A, Midha V, Goyal O et al. Skin and soft tissue infections in cirrhotics: a prospective analysis of clinical presentation and factors affecting outcome. Indian J. Gastroenterol. 2014; 33: 281-284.